Ablation patients (n=16) | |
---|---|
Age, years | 70±15 |
Women, n (%) | 12 (75) |
Body mass index, kg/m2 | 23±4 |
NYHA class III/IV, n (%) | 12 (75) |
Syncope, n (%) | 5 (31) |
Atrial fibrillation, n (%) | 2 (13) |
Previous stroke, n (%) | 2 (13) |
Hypertension, n (%) | 8 (50) |
Diabetes mellitus, n (%) | 2 (13) |
Dyslipidaemia, n (%) | 8 (50) |
Current smoker, n (%) | 2 (13) |
Chronic obstructive pulmonary disease, n (%) | 0 (0) |
Coronary artery disease, n (%) | 1 (6) |
Previous myectomy, n (%) | 0 (0) |
Previous septal ablation, n (%) | 1 (6) |
Family history of HCM, n (%) | 2 (13) |
Intraventricular septum thickness, mm | 15±2 |
End-diastolic diameter, mm | 42±5 |
End-systolic diameter, mm | 23±3 |
Resting LVOT gradient, mm Hg | 107±45 |
LVEF, % | 78±6 |
ICD, n (%) | 5 (31) |
Permanent pacemaker, n (%) | 0 (0) |
β-blocker, n (%) | 16 (100) |
Calcium-channel blocker, n (%) | 6 (38) |
Na channel antagonist, n (%) | 8 (50) |
Amiodarone, n (%) | 1 (6) |
Diuretics, n (%) | 3 (19) |
Warfarin, n (%) | 3 (19) |
Data are expressed as mean±SD or n (%).
HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; NYHA, New York Heart Association.